TrialThe Lancet. Oncology2021
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
Arjun V Balar et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
311 papers cite itlatest 60 shown
this paperpooled ittrialcites it